References

Epidemiological research on diabetic nephropathy at global, regional, and national levels from 1990 to 2021: An analysis derived from the global burden of disease 2021 study

10.3389/fendo.2025.1647064 · 2025 · External reference

IDF diabetes atlas: Global, regional and country‐level diabetes prevalence estimates for 2021 and projections for 2045

10.1016/j.diabres.2021.109119 · 2022 · External reference

Pathophysiology of the diabetic kidney

10.1002/j.2040-4603.2011.tb00365.x · 2011 · External reference

Splanchnic regulation of glucose production

10.1146/annurev.nutr.27.061406.093806 · 2007 · External reference

Type 2 diabetes: Principles of pathogenesis and therapy

10.1016/s0140-6736(05)61032-x · 2005 · External reference

The pathology of Armanni‐Ebstein diabetic nephropathy

1957 · External reference

Glycogen accumulation in renal tubules, a key morphological change in the diabetic rat kidney

10.1007/s00592-005-0188-9 · 2005 · External reference

Influence of long‐term diabetes on renal glycogen metabolism in the rat

10.1159/000045884 · 2001 · External reference

The structure of cardiac glycogen in healthy mice

10.1016/j.ijbiomac.2012.06.037 · 2012 · External reference

Glycogen metabolism in humans

10.1016/j.bbacli.2016.02.001 · 2016 · External reference

Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases

10.1002/med.21867 · 2022 · External reference

Genetic deficiency of glycogen synthase kinase‐3beta corrects diabetes in mouse models of insulin resistance

10.1371/journal.pbio.0060037 · 2008 · External reference

Some molecular structural features of glycogen in the kidneys of diabetic rats

10.1016/j.carbpol.2019.115526 · 2020 · External reference

The effect of streptozotocin‐induced diabetes on glycogen metabolism in rat kidney and its relationship to the liver system

10.1016/0003-9861(79)90250-9 · 1979 · External reference

Structure and segmental localization of glycogen in the diabetic rat‐kidney

10.2337/diab.42.6.891 · 1993 · External reference

Normal and abnormal glycogen structure – A review

10.1016/j.carbpol.2024.122195 · 2024 · External reference

Comparative structural analyses of purified glycogen particles from rat liver, human skeletal muscle, and commercial preparations

10.1016/j.ijbiomac.2009.08.006 · 2009 · External reference

Molecular‐size dependence of glycogen enzymatic degradation and its importance for diabetes

10.1016/j.eurpolymj.2016.07.017 · 2016 · External reference

Interior of glycogen probed by pyrene excimer fluorescence

10.1016/j.carbpol.2022.120205 · 2023 · External reference

A proteomic investigation of the binding agent between liver glycogen beta particles

10.1021/acsomega.8b00119 · 2018 · External reference

Hyperglycemia – A culprit of podocyte pathology in the context of glycogen metabolism

10.1016/j.abb.2024.109927 · 2024 · External reference

Renal glucose metabolism in normal physiological conditions and in diabetes

10.1016/j.diabres.2017.07.033 · 2017 · External reference

Role of hypoxia in the pathogenesis of renal disease

10.1111/j.1523-1755.2005.09909.x · 2005 · External reference

Optimization of molecular design in the evolution of metabolism: The glycogen molecule

10.1042/bj2950477 · 1993 · External reference

The human skeletal muscle glycogenin gene: cDNA, tissue expression, and chromosomal localization

10.1006/bbrc.1996.0359 · 1996 · External reference

Glycogen accumulation in the renal tubular cells of spontaneously occurring diabetic WBN/KOB rats

10.1016/s0021-9975(08)80123-5 · 1990 · External reference

Glucose transporters: Cellular links to hyperglycemia in insulin resistance and diabetes

10.1093/nutrit/nuu012 · 2015 · External reference

Improved glycemic control in mice lacking Sglt1 and Sglt2

2013 · External reference

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic implications

10.1111/j.1464-5491.2009.02894.x · 2010 · External reference

Glucose metabolism in the kidney: Neurohormonal activation and heart failure development

10.1161/jaha.120.018889 · 2020 · External reference

Four grams of glucose

10.1152/ajpendo.90563.2008 · 2009 · External reference

Renal glycogen content and hormonal control of enzymes involved in renal glycogen metabolism

10.1203/00006450-198309000-00017 · 1983 · External reference

Brain glycogen‐new perspectives on its metabolic function and regulation at the subcellular level

2012 · External reference

Glycogen in human peripheral blood leukocytes. I. Characteristics of the synthesis and turnover of glycogen in vitro

10.1172/jci105730 · 1968 · External reference

The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia

10.1111/j.1463-1326.2011.01511.x · 2012 · External reference

Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2

10.1007/s00125-018-4656-5 · 2018 · External reference

Localizations of Na(+)‐D‐glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart

10.1007/s00424-014-1619-7 · 2015 · External reference

Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney

10.1172/jci116392 · 1993 · External reference

Glucose transporters (GLUT and SGLT): Expanded families of sugar transport proteins

10.1079/bjn2002763 · 2003 · External reference

Hepatorenal glucose reciprocity in physiologic and pathologic conditions

2002 · External reference

Physiology of glucose homeostasis

10.1046/j.1463-1326.2000.00085.x · 2006 · External reference

Active sugar transport in health and disease

10.1111/j.1365-2796.2006.01746.x · 2007 · External reference

Glycophagy: Molecular mechanisms, regulatory signals, and disease associations

10.1080/27694127.2025.2595375 · 2026 · External reference

Decoding the molecular mechanism of selective autophagy of glycogen mediated by autophagy receptor STBD1

10.1073/pnas.2402817121 · 2024 · External reference

L‐type glycogen synthase. Tissue distribution and electrophoretic mobility

10.1016/s0021-9258(17)39192-5 · 1985 · External reference

Isozymes of glycogen synthase

10.1016/0014-5793(84)81144-8 · 1984 · External reference

Over‐expression of muscle glycogen synthase in human diabetic nephropathy

10.1007/s00418-014-1290-2 · 2015 · External reference

Attenuation of Armanni‐Ebstein lesions in a rat model of diabetes by a new anti‐fibrotic, anti‐inflammatory agent, FT011

10.1007/s00125-012-2805-9 · 2013 · External reference

Histological changes of the kidney in diabetic nephropathy

2015 · External reference

Intrarenal and urinary glycogen synthase Kinase‐3 Beta levels in diabetic and nondiabetic chronic kidney disease

10.1159/000530210 · 2023 · External reference

GSK‐3β inhibitor induces expression of the TLR4/MyD88/NF‐κB signaling pathway to protect against renal ischemia‐reperfusion injury during rat kidney transplantation

10.1007/s10753-019-01074-2 · 2019 · External reference

The glomerular filtration barrier: A structural target for novel kidney therapies

10.1038/s41573-021-00242-0 · 2021 · External reference

High glucose concentration affects the oxidant‐antioxidant balance in cultured mouse podocytes

10.1002/jcb.23088 · 2011 · External reference

Advanced glycation end‐products induce podocyte injury and contribute to proteinuria

10.3389/fmed.2021.685447 · 2021 · External reference

Insulin resistance in glomerular podocytes: Potential mechanisms of induction

10.1016/j.abb.2021.109005 · 2021 · External reference

Renal podocyte apoptosis in Zucker diabetic fatty rats: Involvement of methylglyoxal‐induced oxidative DNA damage

10.1016/j.jcpa.2010.04.008 · 2011 · External reference

The role of metabolic and haemodynamic factors in podocyte injury in diabetes

10.1002/dmrr.1164 · 2011 · External reference

SIRT1‐AMPK crosstalk is involved in high glucose‐dependent impairment of insulin responsiveness in primary rat podocytes

10.1016/j.yexcr.2016.11.005 · 2016 · External reference

Role of L‐lactate as an energy substrate in primary rat podocytes under physiological and glucose deprivation conditions

10.1016/j.ejcb.2023.151298 · 2023 · External reference

Oxidative and glycolytic metabolism: Their reciprocal regulation and dysregulation in cancer

10.3390/cells14151177 · 2025 · External reference

Epigenetic regulation of the thioredoxin‐interacting protein (TXNIP) gene by hyperglycemia in kidney

10.1016/j.kint.2015.12.018 · 2016 · External reference

Key connexions in progression of diabetic nephropathy

10.1016/j.pharep.2017.12.008 · 2018 · External reference

Mitochondrial metabolic reprogramming in diabetic kidney disease

10.1038/s41419-024-06833-0 · 2024 · External reference

Podocyte bioenergetics in the development of diabetic nephropathy: The role of mitochondria

10.1210/endocr/bqab234 · 2022 · External reference

Silencing of PFKFB3 protects podocytes against high glucose‐induced injury by inducing autophagy

10.3892/mmr.2021.12405 · 2021 · External reference

High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy

10.1096/fj.201600293r · 2017 · External reference

Activation of glycogen synthase kinase 3β ameliorates diabetes‐induced kidney injury

10.1074/jbc.m114.587840 · 2014 · External reference

An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease

10.3389/fphar.2025.1559026 · 2025 · External reference

Glycogen in the diabetic kidney: the hero or the villain?

2018 · External reference

Glycogen synthase kinase 3β dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: Implications for the protective effect of low‐dose lithium in podocytopathy

10.1016/j.ajpath.2014.06.027 · 2014 · External reference

The β isoform of GSK3 mediates podocyte autonomous injury in proteinuric glomerulopathy

10.1002/path.4692 · 2016 · External reference

The redox‐sensitive glycogen synthase kinase 3β suppresses the self‐protective antioxidant response in podocytes upon oxidative glomerular injury

10.18632/oncotarget.6303 · 2015 · External reference

Smad4 promotes diabetic nephropathy by modulating glycolysis and OXPHOS

2020 · External reference

The long‐term effects of metformin on patients with type 2 diabetic kidney disease

10.2337/dc19-0936 · 2020 · External reference

9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes‐2020

10.2337/dc20-s009 · 2020 · External reference

Enhanced release of glucose into the intraluminal space of the intestine associated with metformin treatment as revealed by [(18)F] Fluorodeoxyglucose PET‐MRI

10.2337/dc20-0093 · 2020 · External reference

Metformin: The updated protective property in kidney disease

10.18632/aging.103095 · 2020 · External reference

Low‐dose metformin targets the lysosomal AMPK pathway through PEN2

10.1038/s41586-022-04431-8 · 2022 · External reference

The antidiabetic drug metformin activates the AMP‐activated protein kinase Cascade via an adenine nucleotide‐independent mechanism

10.2337/diabetes.51.8.2420 · 2002 · External reference

The impact of metformin on kidney disease progression and mortality in diabetic patients using SGLT2 inhibitors: A real‐world cohort study

10.1186/s12933-025-02643-6 · 2025 · External reference

Metabolic effects of SGLT2i and metformin on 3‐hydroxybutyric acid and lactate in db/db mice

10.1016/j.ijbiomac.2024.130962 · 2024 · External reference